1. Home
  2. ANGI vs LBRX Comparison

ANGI vs LBRX Comparison

Compare ANGI & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Angi Inc.

ANGI

Angi Inc.

HOLD

Current Price

$8.42

Market Cap

551.9M

ML Signal

HOLD

LBRX

LB Pharmaceuticals Inc

N/A

Current Price

$24.08

Market Cap

602.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ANGI
LBRX
Founded
1995
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
551.9M
602.6M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
ANGI
LBRX
Price
$8.42
$24.08
Analyst Decision
Buy
Strong Buy
Analyst Count
7
3
Target Price
$17.00
$49.00
AVG Volume (30 Days)
1.2M
146.3K
Earning Date
05-06-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
1242.86
N/A
EPS
0.94
N/A
Revenue
$736,386,000.00
N/A
Revenue This Year
$3.64
N/A
Revenue Next Year
$3.75
N/A
P/E Ratio
$10.92
N/A
Revenue Growth
47.60
N/A
52 Week Low
$1.51
$13.40
52 Week High
$19.42
$24.95

Technical Indicators

Market Signals
Indicator
ANGI
LBRX
Relative Strength Index (RSI) 24.83 58.62
Support Level $7.74 $22.90
Resistance Level $8.17 $24.42
Average True Range (ATR) 0.60 1.47
MACD -0.39 0.02
Stochastic Oscillator 8.38 82.56

Price Performance

Historical Comparison
ANGI
LBRX

About ANGI Angi Inc.

Angi Inc connects quality home service professionals with consumers across different categories, from repairing and remodeling to cleaning and landscaping. It operates through brands like Angi, HomeAdvisor, and Handy. The company has three operating segments, namely, Ads and Leads, Services, and International (Europe and Canada). A majority of its revenue is generated from the Ads and Leads segment, which provides professionals the capability to engage with potential customers, including quoting and invoicing services, and provides consumers with tools and resources to help them find professionals nationwide for home repair, maintenance, and improvement projects. Geographically, the company derives its key revenue from the United States and also has a presence in other countries.

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.

Share on Social Networks: